-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Show Me the Data™: Pushing CAR T’s Forward Across Lymphoid Malignancies... Accelerating Access in the Community and Treatment Strategies for the Road Ahead

Sponsor: Autolus Limited and Novartis Pharmaceuticals Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Lymphomas, B Cell lymphoma, Education, Diseases, Lymphoid Malignancies
Friday, December 6, 2024: 7:00 PM-10:00 PM
Ballroom 20CD (San Diego Convention Center)
Chair:
Alexey V. Danilov, MD, PhD, City of Hope National Medical Center
Disclosures:
No relevant conflicts of interest to declare.
Speakers:
Lori A. Leslie, MD, John Theurer Cancer Center, Hackensack University Medical Center , Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Center , Jason R. Westin, MD, ARRAY(0xfd2b2f8) and Leidy L. Isenalumhe, MD, MS, Moffitt Cancer Center
Disclosures:
Leslie: Beigene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Lily: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite, a Gilead Company: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Consultancy; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TG Therapeutics: Consultancy, Speakers Bureau; Astrazeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche/Genenetech: Consultancy, Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Evolveimmune: Consultancy; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Karyopharm: Consultancy; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Seagen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Consultancy. Westin: AbbVie/GenMab: Consultancy; Allogene: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Regeneron: Consultancy; Nurix: Consultancy, Research Funding; Kite/Gilead: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Genentech, Inc.: Consultancy, Research Funding; Morphosys/Incyte: Consultancy, Research Funding; ADC Therapeutics: Consultancy, Research Funding. Isenalumhe: Amgen: Consultancy; Jazz Pharmaceuticals: Consultancy.

On Demand program will be available here December 7, 2024.

Access Program Here

The live portion of this curriculum will be presented as a 3.0-hour Friday Satellite Symposium (FSS) held prior to the 2024 ASH Annual Meeting. This agenda has been developed in an interactive Show Me the Data format where experts will lead case-based panel discussions regarding the latest clinical advances in treating and managing patients with B-cell malignancies with novel T-cell therapy with novel treatment approaches and emerging treatment strategies in the context of current paradigms. After each 'decision point' presentation, one faculty from the panel will convene to share their practice preferences and perspectives on the clinical trial data and clinical pearls from their practices. The chair will then challenge the faculty member to show them the data that backs up their decision making. Faculty will be probed on how emerging strategies under investigation may impact future treatment decision making. The program will also feature an interactive question-and-answer session between the faculty and attendees to emphasize areas of educational need, highlight areas of debate, and illustrate the application of new data in defined clinical situations.